Skip to main content
Premium Trial:

Request an Annual Quote

Tony Coles

CRISPR Therapeutics has named Tony Coles to its board of directors. Coles is Chairman and CEO of Yumanity Therapeutics. Prior to that, he was Chariman and CEO  of Onyx Pharmaceuticals. 

Coles has an MD from Duke University , a master's in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. He completed his medical training in cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School.

Coles also serves on the board of directors at McKesson and the board of trustees for Johns Hopkins and Johns Hopkins Medicine.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.